Skip to main content
Equibles

PHM · PHARMA MAR, S.A. · Financials

Use PHM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PHM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
69.6500 EUR -1.7500 (-2.45%) At close · Oct 5
Rebalance outlook locked
Market Cap
1.28B EUR
Shares
17.29M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →

Browse captured authority reports and their original financial labels

Revenue
221.39M +26.6%
FY2025 Revenue FY2019–FY2025
Net Income
74.99M +187%
FY2025 Net Income FY2019–FY2025
Gross Margin
94.46% -0.9pp
FY2025 Gross Margin FY2019–FY2025
Operating Margin
27.42% +23.7pp
FY2025 Operating Margin FY2019–FY2025
Operating Cash Flow
53.13M +781.5%
FY2025 Operating Cash Flow FY2019–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
EUR 221.39M 174.86M 158.15M 196.34M 229.83M 269.96M 85.82M
EUR 12.26M 8.18M 9.61M 13.64M 16.44M 13.72M 5.23M
EUR 209.13M 166.67M 148.54M 182.7M 213.39M 256.24M 80.59M
EUR 95.19M 103.5M 99.3M 83.45M 72.17M 53.79M 50.64M
EUR 30.71M 24.37M 18.26M 19.02M 17.37M 13.52M 13.88M
EUR 60.72M 6.47M -3.83M 44.07M 92.45M 155.94M -17.49M
EUR 6.51M 8.53M 9.43M 11.29M 7.68M 15.38M 4.37M
EUR 59.65M 11.99M -3.62M 43.79M 95.13M 145.61M -21.65M
EUR -15.34M -14.14M -4.76M -5.57M 2.27M 8.34M -12.47M
EUR 74.99M 26.13M 1.14M 49.36M 92.86M 137.26M -11.38M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: 252.66M in buybacks, 68.51M in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current borrowings, including current portion of noncurrent borrowings 2025-12-31 EUR 3,016,000 ESEF Annual Report filed 2026-02-27
Current lease liabilities 2025-12-31 EUR 11,026,000 ESEF Annual Report filed 2026-02-27
Noncurrent lease liabilities 2025-12-31 EUR 1,131,000 ESEF Annual Report filed 2026-02-27
Noncurrent long-term borrowings 2025-12-31 EUR 35,552,000 ESEF Annual Report filed 2026-02-27
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.